Junning Cao

Efficacy and safety of geptanolimab (GB226) for relapsed/refractory primary mediastinal large B-cell lymphoma: an open-label phase II study (Gxplore-003)

Chuan Jin, Zhi-gang Peng, Xiao-hong Zhang, 2023, Cancer Immunology, Immunotherapy.

The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial

Jun Yu Li, Dengju Li, Zengjun Li, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Preliminary Safety and Efficacy of Zanubrutinib in Combination with Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Junjie Cao, Shan Huang, Ye Guo, 2022, Blood.

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

L. Sehn, Junjie Cao, H. Tilly, 2023, Blood.